Pfizer, Eli Lilly, Novartis, Bristol Myers Squibb and AstraZeneca are all ramping up the use of AI, but drug discovery is not the primary success story—yet.
Vertex Pharmaceuticals (NasdaqGS:VRTX) entered an agreement with WuXi Biologics to co-develop a trispecific T-cell Engager ...
The new year brought a slew of new faces in the pharma and biotech world, especially in the top jobs, with a number of CEO ...
Large drugmakers once had more room to absorb failure, both financially and reputationally | Large drugmakers are facing tighter constraints than in the past, as financial, scientific and reputational ...
Background Preventing high heart rates in atrial fibrillation (AF) is recommended to reduce AF-related symptoms and morbidity. Evidence on a strong relationship between lower heart rate during AF and ...
Wanxiang A123 Systems Corp. unveiled a next-generation safety solution at its "Gathering Stars, Smart Storage Future" event, introducing ...
OXB and Bristol Myers Squibb (BMS) are expanding a partnership regarding manufacture and supply of lentiviral vectors for BMS ...
Bristol Myers stock is volatile ahead of earnings as investors weighed its expanded OXB manufacturing deal and recent bullish ...
The latest OXB agreement will help advance the company’s CAR-T therapies and provide a “reliable, scalable manufacturing ...
Oxford, UK – 4 February 2026: OXB (LSE: OXB), a global quality and innovation-led cell and gene therapy CDMO, today announces ...
AbbVie (NYSE:ABBV) has agreed to acquire Capstan Therapeutics to expand its work in in vivo CAR-T cell therapy. The company ...
BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced another major independent validation of its AI and machine learning (ML) capabilities in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results